Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics
Sarepta Therapeutics’ $313.5 Million Convertible Senior Notes Exchange
Ropes & Gray advised Sarepta Therapeutics on the deal. Sarepta Therapeutics, Inc. announced separate, privately negotiated exchange agreements with certain holders of its 1.50% Convertible Senior...